A peculiar application currently under investigation is the scenario of clonal hematopoiesis of indeterminate potential (CHIP) or its age-related counterpart ARCH (age-related clonal hematopoiesis), especially sustained by TET2 mutations, where the consideration of a simple, over-the-counter supplementation of high-dose of vitamin C may represent an appealing option in decelerating progression to overt, fully-blown myeloid neoplasms (MDS/AML) (Miller and Steensma, 2020). The gene discussed is TET2; the disease is acute myeloid leukemia.